Consumer Healthcare Products Association
Manufacturers & distributors of non-prescription OTC medicines and dietary supplements.
Based in DC
AI Overview
With $1.5M in lobbying spend across 29 quarterly filings, Consumer Healthcare Products Association is a significant lobbying presence. Their lobbying covers 4 issue areas. Active from 2018 to 2025.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2018 | $200K |
| 2019 | $100K |
| 2020 | $200K |
| 2021 | $200K |
| 2022 | $200K |
| 2023 | $200K |
| 2024 | $240K |
| 2025 | $180K |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Alcohol & Drug Abuse, Taxation, Health Issues, Pharmacy
Issues related to the sale of medicines that contain dextromethorphan, including H.R. 1271, the DXM Abuse Prevention Act of 2017.
Issues related to the eligibility of over the counter drugs to be purchased using HSA and FSA accounts, including H.R.394 and S.85, both entitled Restoring Access to Medication Act of 2017, and H. R. 4618.
Issues related to the over the counter drug monograph process including H. R. 5333, the Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018 and S. 2315, the Over-the-Counter Drug Safety, Innovation, and Reform Act.
General issues related to over the counter pharmaceuticals. Issues related to draft legislation addressing the over the counter drug monograph process including H. R. 5333, the Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018 and S. 2315, the Over-the-Counter Drug Safety, Innovation, and Reform Act.
Issues related to the eligibility of over the counter drugs to be purchased using HSA and FSA accounts, including H.R.394 and S.85, both entitled Restoring Access to Medication Act of 2017, H. R. 4618, and H. R. 6199.
Issues related to the sale of medicines that contain dextromethorphan, including H. R. 863, the DXM Abuse Prevention Act of 2019.
Issues related to the over the counter drug monograph process including H.R.269, the Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 and H. R. 3443, the Over-the-counter Monograph Safety, Innovation, and Reform Act of 2019. Issues related to sunscreen.
Issues related to the eligibility of over the counter drugs to be purchased using HSA and FSA accounts, including H.R. 1922.
Showing 8 of 20 unique descriptions from filings.
Related Analysis
Related Investigations
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.